Review top news and interview highlights from the week ending February 9, 2024.
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
The new Cell and Gene Therapy Access Model will be led by the Centers for Medicare & Medicaid Services’ Innovation Center.
The chief scientific officer of CureDuchenne discussed how nonviral approaches may address issues including gene size and redosability.
AK-OTOF delivers transgenes encoding OTOF, the disease-targeted gene, to the inner hair cells of the cochlea via a single unilateral intracochlear administration.
The associate professor of dermatology at Stanford University discussed the potential impact of Vyjuvek’s approval in the derm field.
Orchard Therapeutics has also randomized the first patient with Hurler Syndrome in the phase 3, registrational HURCULES trial of OTL-203 gene therapy.